New cell therapy B019 takes on tough lymphoma in first human trial

NCT ID NCT06970496

Not yet recruiting Disease control Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This early-stage trial tests a new cell therapy called B019 in 48 people with relapsed or refractory B-cell non-Hodgkin's lymphoma. The main goals are to check safety and find the right dose. Researchers will also look for early signs that the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: B019 (a cell therapy given as an intravenous infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat B-cell lymphoma.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The treatment may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA

Contacts and locations

Locations

Jiangxi Cancer Hospital

Nanchang, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China
Shanghai General Hospital

Shanghai, China
Sun Yat-sen University Cancer Center

Guangzhou, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, China
Xijing Hospital

Xi'an, China
Zhujiang Hospital of Southern Medical University

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.